Total raised
—
Stage
Pre-Funding
Founded
2017
Headcount
6
HQ
Sector
Health Tech & Life Sciences
About
BARcure provides a therapeutic platform applicable to various B-cell neoplasms, primarily non-Hodgkins lymphoma (NHL). The company is currently focusing on the development of two BAR-based products for the treatment of DLBCL and MCL. BARcure specifically targets malignant B cells with novel immunotherapies designed to kill tumor cells while sparing normal B cells. The company leverages the robust research work done by Prof. Michael Pfreundschuh from Saarland University in Germany.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
biopharmaceuticalimmunologytherapeuticsdrug-deliverycancerpharmaceuticalsimmuno-theraphyoncologyimmunotherapy